A Prospective, Randomized, Multi-centre Trial evaluating Efficacy, Quality of Life and Safety of Sacral Neuromodulation vs Standard Medical Treatment in Subjects with Symptoms of Overactive Bladder

Griebling T L1, Zylstra S2, Bennett J3, Mangel J4, Bird E5, Pinson T6, Culkin D7, Sutherland S E8, Kan F9, Comiter C10, Siegel S11

Abstract Category

Neurourology: Clinical

Abstract 108
Neurourology 1
Scientific Podium Poster Session 12
Wednesday 28th August 2013
16:35 - 16:40
115
Clinical Trial Neuromodulation Overactive Bladder Quality of Life (QoL)
1. Urology and The Landon Center on Aging, University of Kansas, Kansas City, KS, USA, 2. OBGYN, Milford Regional Medical Center, Whitinsville, MA, USA, 3. Urogyn, Female Pelvic Medicine, Grand Rapids, MI, USA, 4. OBGYN, MetroHealth Medical Center, Cleveland, OH, USA, 5. Urology, Scott and White Healthcare, Temple, TX, USA, 6. Urology, Pinson Urology Center, Jackson, MI, USA, 7. Urology, University of Oklahoma HSC, Oklahoma City, OK, USA, 8. Centers for Continence Care and Female Urology, Metro Urology, Plymouth, MN, USA, 9. Medtronic Inc., Minneapolis, MI, USA, 10. Stanford University, Stanford, CA, USA, 11. Centers for Continence Care and Female Urology, Metro Urology, Woodbury, MN, USA
Presenter
T

Tomas L Griebling

Links

Abstract

17/04/2024 13:07:52